Drug intelligence / Profile preview

interleukin-5

Development stage: Preclinical
Lead developer: Sanofi
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Inhalation, Topical Instillation

Overview

Interleukin-5 (IL-5) is a T-helper type 2 (Th2) cell-derived cytokine that plays a critical role in the pathogenesis of allergic bronchial asthma. It mediates the terminal differentiation of committed eosinophil precursors, activates mature eosinophils, and prolongs their survival. IL-5 also selectively enhances eosinophil degranulation, antibody-dependent cytotoxicity, and adhesion to vascular endothelium. Studies have shown that recombinant human IL-5 can induce eosinophil infiltration into asthmatic airways and increase airway hyperresponsiveness. It is considered a potential therapeutic target for asthma.

Other names: IL-5IL5IL 5

Targets

IL-5R (Interleukin-5 receptor)

Beyond the preview

Go deeper on interleukin-5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interleukin-5.

Explore the full profile